Early treatment with phosphate-binders and active metabolites of vitamin D in prevention of secondary hyperparathyreoidism in patients with chronic kidney disease on program hemodialysis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. Assessment of efficacay of early start of correction of calcium-phosphate metabolism disturbances in patients on program hemodialysis in prevention of secondary hyperparathyreoidism. Methods. 128 patients with chronic kidney disease (CKD) stage З - 5D were included into the study: 89 (69,5 %) with chronic glomerulonephritis, ЗО (23,4 %) - with chronic tubulo-interstitial nephritis, 9 (7,1 %) - with hypertensive nephrosclerosis. 82 (64,і %) of included patients had calcium-phosphate metabolism disturbances. According to the previous therapy patients were divided into З groups: 1st (n = 26) - received alfacalcidol per os in predialysis period and intravenously in program hemodialysis, 2nd (n = 26) - paricalcitol per os in predialysis period and intravenously in program hemodialysis, 3rd (n = ЗО) - did not received active vitamin D metabolits in predialysis period, but received intravenous alfacalcidol or paricalcitol on program hemodialysis. 32 (ii -from the 1st group, ii - from the 2nd group, io - from the 3rd group) patients were followed for 5 years. In ΙΟ patients on program hemodialysis, who did not demonstrate adequate decrease of intact parathyreoid hormone клиническая нефрология 6 - 2013 оригинальные статьи (iPTH), active vitamin d metabolits were combined with cinacalcet. All patients before active vitamin d metabolits started receiving phosphate-binders. In all patients in the beginning and in the end of follow-up ultrasound scanning of common carotid arteries was performed. Results. In 3 months after alfacaclidol or paricalcitol start in patients of 1st and 2nd groups normalization of iPTH level was seen. In 6 months paricalcitol lead to more prominent decrease of bp and proteinuria, than alfacalcidol. In combination with ace inhibitors paricalcitol induced decrease of bp and left ventricular myocardial mass index to a greater extent, than alfacalcidol. In patients of 1st and 2nd group, in whom iPTH level was normalized during pre-dialisys period, chronic kidney disease progression was less rapid. 22 patients of 1st and 2nd groups with normalized iPTH level in pre-dialisys period, during first 3 years of hemodialysis secondary hyperparathyreoidism did not develop. ΙΟ patients of 3rd group developed secondary hyperparathyreoidism with ectopic calcification in 3 patients and calciphylaxy in I patient. Conclusion. Inadequate correction of secondary hyperparathyreoidism in pre-dialysis period leads to inefficacy of treatment of secondary hyperparathyreoidism on program hemodialysis with ectopic calcification and calciphylaxy development.

Full Text

Restricted Access

References

  1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evalution, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) // Kidney Int. - 2009. - Vol. 76(Suppl.113). -P. S1-S130.
  2. Национальные рекомендации по минеральным и костным нарушениям при хронической болезни почек: Российское диализное общество (май 2010) // Нефрология и диализ. - 2011. - № 13(1). - P. 33-51.
  3. Milovanova L., Milovanov Y., Plotnikova A. Phosphorus and Calcium Metabolism Disorders Assosiated with Chronic Kidney Disease Stage III-IV: Systematic Rewiew and Meta-Analysis // Chronic Kidney Disease and renal Transplantation. - 2012. - Р. 95-118.
  4. Милованова Л.Ю., Милованов Ю.С., Плотникова А.А. и др. Эктопическая минерализация при хронической болезни почек - механизмы, патогенез, современные возможности профилактики и лечения // Современная медицинская наука. - 2012. - Vol. 1. - P. 16-33.
  5. Добронравов В.А. Современный взгляд на патофизиологию вторичного гиперпаратиреоза: роль фактора роста фибробластов 23 и Klotho // Нефрология. - 2011. - Vol. 15(4). - P. 11-20.
  6. Clinical Practice Guideline for the Management of Chronic Kidney Disease. KDIGO//Kidney Int. Suppl. - 2013. - Vol. 3(1).
  7. Martin K.J., Gonzalez M.G., Gonzalez E.A. et al. 19-Nor-1-a-25 Dihydroxyvitamin D2 (Paricalcitol) safety and affectively reduces the levels of the intact Parathyroid Hormone in patients on Hemodialysis // J. Am. Soc. Nephrol. - 1998. - Vol. 9. - P. 1427-1432.
  8. Schumock G. T., Arruda J. A., Marx S. E. et al. Pharmacoeconomic analysis of paricalcitol and calcitriol in the treatment of secondary hyperparathyroidism in haemodialysis: impact ofhospitalisations and survival// J. Med. Econ. - 2007. -Vol. 10. - P. 393-409.
  9. Милованова Л.Ю., Милованов Ю.С., Добросмыслов И.А. Вторичный гиперпаратиреоз у больных хронической болезнью почек. Роль фактора роста фибробластов-23 (FGF-23) и Klotho //Клин. нефрол. - 2013. -№ 1. - С. 14-19.
  10. Lindberg J., Martin K.J. , Gonzales E.A. et al. A long-term, multicenter study of the efficacy and safety of parycalcitol in end-stage renal disease // Clin. Nephrol. - 2001. - Vol. 56. - P. 315-323.
  11. Sprague S.M., Llach F., Amdahl M. et al. Paricacitol versus calcitriol in the treatment of secondary hyperparathyroidism//Kidney Int. - 2003. - Vol. 63. -P. 1483-1490.
  12. Llach F., Yudd M. Paricalcitol in Dialysis Patients with calcitriol-resistant secondary hyperparathyroidism // Am. J. Kid. Dis. - 2001. - Vol. 38(suppl5). - P. S45-S50.
  13. Teng M., Wolf M., Lowrie E. et al. Survival of Patients Undergoing hemodialysis with paricalcitol or Calcitriol therapy // New. Engl. J. Med. - 2003. -Vol. 349. - P. 446-456.
  14. Плотникова А.А., Милованова Л.Ю., Милованов Ю.С. Парикальцитол -новые возможности оптимизации нефропротективной стратегии и лечения вторичного гиперпаратиреоза // Клин. нефрол. - 2012. -№ 4. - С. 51-55.
  15. Milovanov Y.S., Milovanova L.Y., Kozlovskaya L.V. Role of Vitamin D Receptor Selective Activator Paricalcitol in Nephroprotective Strategy in Chronic Kidney Disease // Inrern. J. Biomed. - 2011. - Vol. 1(4). - P. 199-203.
  16. Milovanova L.Yu., Milovanov Yu.S., Kozlovskaya L.V. The place of paricalcitol in nephroprotrctive strategy of predialysis chronic kidney disease due to systemic diseases//Arh. Evromed. - 2011. - Vol. 3. - P. 69-78.
  17. Schumock G.T. Comparative Effectiveness of Paricalcitol versus Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis // Nephron Clin. Pract. - 2010. - Vol. 117(2). - P. 151-159.
  18. Dobrez D.G., Mathes A., Amdahl M. et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings// Nephrol. Dial. Transplant. - 2004. -Vol. 19. - P. 1174-1181.
  19. Милованов Ю.С., Милованова Л.Ю., Моисеев С.В. Выбор фосфатсвязывающего препарата для лечения гиперпаратиреоза при хронической болезни почек: эффекты на кальцификацию артерий и смертность // Клиническая фармакология и терапия. - 2012. - № 5. -С. 46-52.
  20. Милованова Л.Ю., Милованов Ю.С.,Добросмыслов И.А. и др. Севеламерагидрохлорид-новые перспективы в коррекциигиперфосфатемии у больных хронической болезнью почек 3-4-й стадий // Клин. нефрол. - 2012. -Vol. 5-6. - P. 49-53.
  21. Weenig R.H. Pathogenesis of calciphylaxis: Hans Selye to nuclear factor kappa-B// J. Am. Acad. Dermatol. - 2008. - Vol. 58(3). - P. 458-71.
  22. Weenig R.H., Sewell L.D., Davis M.D. et al. Calciphylaxis: natural history, risk factor analysis, and outcome// J. Am. Acad. Dermatol. - 2007. - Vol. 56(4). -P. 569-79.
  23. Li J.Z., Huen W. Images in clinical medicine. Calciphylaxis with arterial calcification // N. Engl. J. Med. - 2007. - Vol. 357(13). - P. 1326.
  24. Mehta R.L., Scott G., Slound J.A. et al. Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis // Am. J. Med. - 1990. - Vol. 88. - P. 252.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies